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Summary
Objective: Glucosamine is commonly used for the treatment of osteoarthritis, and its use is increasing in the general population. The Canadian
Multicentre Osteoporosis Study (CaMos) provided an opportunity to examine the prevalence of glucosamine use across age and gender
groups, and to assess the factors associated with its use.
Method: CaMos is a random, population-based sample of 9423 Canadians. Baseline assessments took place in 1996e1997 and the 5-year
follow-up assessments in 2001e2002. The primary outcome of this analysis was glucosamine use at year 5. Prevalence estimates were age-
and sex-standardized to the Canadian population. A number of factors potentially associated with glucosamine use were identiﬁed from the
literature. Multivariable logistic regression was used to identify variables associated with glucosamine use.
Results: At 5 years, complete data were available for 7652 of the original 9423 participants (81.2%). For men, glucosamine use increased from
0.9% to 4.7% (weighted values), and for women, it increased from 1.3% to 8.2%. Glucosamine use was higher among older participants, those
living in western Canada, and those with arthritis, back pain, higher calcium intake from supplements, physical activity and prior glucosamine
use.
Conclusions: Glucosamine use increased substantially over 5 years, and its use is associated with a number of factors. Some may use
glucosamine to manage pain and symptoms of arthritis and back pain, while others use it as a preventive measure to maintain health.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.






Complementary and alternative medicine (CAM) refers to
a diverse group of therapies not considered to be a part
of conventional medicine. CAM falls into four general cate-
gories, including alternative medical systems such as
acupuncture and naturopathy; biologically based therapies
(BBT) such as certain diets, supplements and megavitamin
therapy; manipulative and body-based therapies such as
chiropractic care and massage; and mind-body therapies
such as prayer, meditation and yoga1. These therapies
are used as a substitute for or in conjunction with conven-
tional medicine, and their use is at an all-time high1,
particularly among those over 50 years of age2.
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Received 1 February 2006; revision accepted 5 June 2006.12Data from 2002 indicate that 62% of American adults had
used some form of CAM in the previous 12 months1. Cana-
dian data from the same year suggest that the rate of
supplement use is similar in Canada and the US3, while
data from 2005 suggest that 71% of those surveyed had
used a natural health product (NHP) at some time in their
life4. NHPs are similar to the BBT category of CAM and
include products such as vitamins and minerals, herbal
remedies or plant extracts, homeopathic and traditional
medicines, amino acids and essential fatty acids4.
According to the National Health Interview Survey, use of
CAM is higher for those who report a diagnosis of arthritis
(41.1%) as compared to those without arthritis (34.6%),
with nonvitamin, nonmineral products cited as the most
frequently used (20.1%)5. A random sample of 612 primary
care patients with arthritis or ﬁbromyalgia found that 90.2%
reported CAM use for arthritis at some point, with 34.1%
reporting current use of oral supplements, mainly glucos-
amine and chondroitin6.
Use of glucosamine compounds in the management of
osteoarthritis has attracted a great deal of attention,88
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scientiﬁc community7. In 2002, glucosamine was one of the
top ﬁve natural products used in the US general population,
being used by approximately 14% of those who reported
using an herbal or other natural product (other than vitamins
or minerals) in the past 12 months1. In a 5-year retrospec-
tive study of 22 supplements purchased by an elderly
cohort, glucosamine was identiﬁed as the most frequently
used nonvitamin, nonmineral supplement8.
Non-steroidal anti-inﬂammatory drugs remain the treat-
ment of choice for pharmacological management of arthritis,
but there are side effects to these treatments, and as a re-
sult, patients have looked to CAM and particularly glucos-
amine-containing products as an alternative7,9. Athletes at
all ages and levels of participation have also embraced
glucosamine as a treatment for arthritis, pain and swelling
associated with injury10. Efﬁcacy data have shown promis-
ing results9,11,12, although a recent Cochrane Review sug-
gests that the effectiveness may depend on the outcome
measured and the brand of glucosamine used7. They noted
that pooled results from studies using the Rotta preparation
found glucosamine to be superior to placebo in the treat-
ment of pain and functional impairment, while studies using
a non-Rotta preparation failed to show a beneﬁt in pain and
function. Neither was superior to placebo when the outcome
was the Western Ontario and MacMaster Osteoarthritis
Index (WOMAC13). In addition, the Glucosamine/chondroi-
tin Arthritis Intervention Trial (GAIT) was also unable to
ﬁnd conclusive evidence of efﬁcacy14,15.
Despite ongoing questions regarding effectiveness,
glucosamine is commonly believed to be useful for the treat-
ment of osteoarthritis, and its use is increasing in the
general population2,14. The Canadian Multicentre Osteopo-
rosis Study (CaMos), a random, population-based sample
of 9423 Canadians, provided an opportunity to examine
the prevalence of glucosamine use across age and gender
groups, and to assess the factors associated with its use.
Methods
CaMos is an ongoing, prospective cohort study of 9423
non-institutionalized, randomly selected men and women
aged 25 years and older at baseline, drawn from a 50-km
radius of nine Canadian cities (St John’s, Newfoundland;
Halifax, Nova Scotia; Quebec City, Quebec; Toronto,
Ontario; Hamilton, Ontario; Kingston, Ontario; Saskatoon,
Saskatchewan; Calgary, Alberta; and Vancouver, British
Columbia). Baseline assessments took place between Feb-
ruary 1996 and September 1997 and the 5-year follow-up
assessments between February 2001 and September
2002. Ethics approval was obtained through the Review
Boards of each participating center.
A detailed description of the objectives, methodology and
sampling framework for CaMos is available elsewhere16.
Brieﬂy, households within each region were selected by
random draws of listed telephone numbers, and one ran-
domly selected household member 25 years of age was
asked to participate in the study. Participation involved a de-
tailed, in-person interview at baseline, which was conducted
by CaMos staff who received centralized training in inter-
view techniques and the administration of the standardized
questionnaires. The interview covered sociodemographic
factors, medical and family history, food intake and lifestyle
questions. Participants were also asked to bring with them
all medications and supplements currently taken. They
completed a short questionnaire annually thereafter, and
returned for a full interview at 5 years.CaMos was designed to collect epidemiological data
related to the incidence and prevalence of osteoporosis.
As a result, the sampling framework, although random,
was designed to include more women than men, and higher
numbers of older compared to younger Canadian residents.
Our prevalence estimates were therefore age- and sex-
standardized using simple direct standardization to the
Canadian population, using Statistics Canada data from
2002. In order to project our rates across all of Canada,
centers represented not only their city but also their prov-
ince or region. For example, Halifax represented most of
Atlantic Canada, including Nova Scotia, Prince Edward
Island and New Brunswick, while Kingston represented
only a small proportion of Ontario residents since Hamilton
and Toronto were also included in the sample.
The primary outcome was glucosamine use, as reported
at year 5. Participants were considered as positive for
glucosamine use if they took glucosamine sulfate or glucos-
amine hydrochloride alone or in any preparation that listed
glucosamine as one of the ingredients. All glucosamine
products were available without a prescription. Length of
time that the product was taken was not asked, but in order
to be considered positive, it had to be taken on a regular ba-
sis. Factors potentially associated with glucosamine use
were identiﬁed on the basis of a review of the existing liter-
ature and clinical input. These included age, gender, center,
arthritis, osteoporosis, family history of arthritis, history of
fracture, education level, history of back pain, body mass
index (BMI, based on measured height and weight), use
of calcium from supplements, time spent walking (typical
week in the past 6 months), participation in regular activity
(any regular activity or program), overall activity level
(as compared to peers) and glucosamine use at
baseline1,2,4e7,10,17.
The independent variables included a combination of
those assessed at baseline (e.g., center, gender, education
level, and baseline glucosamine use) and at year 5 (e.g.,
activity level, BMI, and calcium from supplements).
Conditions that could change during the 5-year follow-up,
including arthritis, osteoporosis and fracture, were catego-
rized as ‘‘no’’, ‘‘yes at baseline’’ and ‘‘yes developed since
then’’ as their development over time could impact on glu-
cosamine use. Rheumatoid arthritis and osteoarthritis
were based on self-report, within the context of a clinical
diagnosis (‘‘Has a doctor ever told you that you have.’’).
However, participants were not always clear as to which
they had, so these two were combined for this analysis.
Back pain (yes/no) was also based on the participants’
response as to whether they had ever experienced it. Cal-
cium intake was measured in milligrams, on the basis of
intake from supplements, and was analyzed overall and
by 300-mg increments (the equivalent of the calcium in
a serving of milk). Race and ethnicity were considered,
but 94.9% of the sample were described as ‘‘white’’, result-
ing in insufﬁcient numbers of other groups for accurate
comparisons.
Descriptive statistics were generated by gender and for
each of six age strata, beginning with 30e39 years and
ending with 80 years and over. Participants were 25 years
and older at baseline, but were 30 years and older at the
time of the 5-year follow-up. The association between
each variable and glucosamine use was examined using
univariate logistic regression. Interactions between the
variables were not tested. Multivariable logistic regression
modeling was used to assess the effects of the independent
variables on glucosamine use. The Bayes Information Crite-
ria (BIC) model selection criterion18 was used for model
1290 W. M. Hopman et al.: Glucosamine use in Canadaselection. The BIC provides approximate Bayes factors,
which are then used to compare how well the data ﬁt
each model.
Results
Complete data were available for 5430 of the original
6539 women (83.0%) and for 2222 of the original 2884
men (77.0%). Data were missing for 1771 (18.8%) partici-
pants for the following reasons: 644 (6.8%) had died by
the time of follow-up; 429 (4.6%) completed a short ques-
tionnaire over the telephone rather than returning for a full
interview; 260 (2.8%) could not be contacted; 117 (1.2%)
were no longer interested; 98 (1.0%) were too sick; 123
(1.3%) had moved away; and 100 (1.1%) cited miscella-
neous reasons such as canceled, no time or no reason
given.
At baseline, 151 participants (34 or 1.2% of the men, 117
or 1.8% of the women) were taking glucosamine. Of these,
59 (39.1%) were still taking it at year 5, 64 (42.2%) had
stopped taking it, and 28 (18.5%) did not have complete
data at year 5 for a variety of reasons including death
(10), a short telephone questionnaire only (12), too sick
(2), and single cases of telephone number changed, no lon-
ger interested, moved away, and no time.
Table I contains the unadjusted frequencies for the sam-
ple characteristics, by gender. A much larger percentage of
Table I
Unadjusted frequencies for sample characteristics
Characteristic Unadjusted frequencies n (%)
Male Female
Sample size*
Year 5 2222 (100) 5430 (100)
Glucosamine use
Baseline 34 (1.2) 117 (1.8)
Year 5 189 (8.5) 694 (12.8)
Age group in years
30e39 149 (6.7) 168 (3.1)
40e49 175 (7.9) 261 (4.8)
50e59 486 (21.9) 1023 (18.8)
60e69 553 (24.9) 1454 (26.8)
70e79 626 (28.2) 1774 (32.7)
80þ 233 (10.5) 750 (13.8)
Center
St. John’s, Newfoundland 210 (9.5) 591 (10.9)
Halifax, Nova Scotia 239 (10.8) 597 (11.0)
Quebec City, Quebec 257 (11.6) 668 (12.3)
Kingston, Ontario 236 (10.6) 607 (11.2)
Toronto, Ontario 217 (9.8) 480 (8.8)
Hamilton, Ontario 263 (11.8) 631 (11.6)
Saskatoon, Saskatchewan 278 (12.5) 632 (11.6)
Calgary, Alberta 267 (12.0) 614 (11.3)
Vancouver, British Columbia 255 (11.5) 610 (11.2)
Educationy
<Grade 9 220 (9.9) 634 (11.7)
Grade 9e13, No Diploma 448 (20.2) 1354 (24.9)
High School Diploma 288 (13.0) 850 (15.7)
Trade/Professional Diploma 398 (17.9) 1210 (22.3)
University without Diploma 183 (8.2) 392 (7.2)
University with Diploma 100 (4.5) 262 (4.8)
University Degree(s) 585 (26.3) 728 (13.4)
*At baseline, N¼ 2884 men and 6539 women.
yFor Education, all references to a diploma were collected as
‘‘Certiﬁcate or Diploma’’.participants used glucosamine at year 5 as compared to
baseline. For men, unadjusted glucosamine use increased
from 1.2% at baseline to 8.5% at year 5 (weighted values
were 0.9% to 4.7%), and for women, it increased from 1.8%
to 12.8% (weighted values were 1.3% to 8.2%). Table II
contains the weighted percentages of men and women using
glucosamine at year 5, within each age group, center and by
education level. There was an increase in glucosamine use
with increased age for both men and women. Glucosamine
use was somewhat higher in the western centers of Saska-
toon, Calgary and particularly Vancouver as compared to
the Atlantic, Quebec and the three Ontario centers. Use
was somewhat higher in men with more education than in
those at lower levels of education. The opposite was true
for women, with greater use at the lower levels of education.
When examining the weighted values for BMI, men using
glucosamine had a lower mean BMI (26.8 3.0) than those
who did not (27.3 5.2). This was reversed for women, where
those who were taking glucosamine had a higher mean BMI
(27.6 3.8) than those who were not (26.3 5.0). In addition,
men taking glucosamine had a higher weightedmean calcium
intake from supplements (278.8 410.3 mg) than those who
did not (116.4 394.7 mg), which also held true for women,
at 567.9 321.8 mg for those taking glucosamine and
305.0 388.9 for those who did not.
Table III provides the percentages of participants with
arthritis, osteoporosis, family history of arthritis, history of
fracture and history of back pain, as well as the percentages
using glucosamine within each response category. For
three of these (arthritis, osteoporosis and fracture), data
are presented separately for those who had the condition
at baseline or developed it since that time. Glucosamine
Table II
Glucosamine use at year 5, using values standardized to the Cana-
dian population. Percentages reflect the number of users within
each age group, Center or education level
Characteristic Percent and 95% CI
Male Female
Age group in years
30e39 0.4 (0.0e0.8) 1.9 (1.0e2.7)
40e49 1.6 (0.8e2.4) 3.8 (2.6e4.9)
50e59 7.7 (5.8e9.6) 12.5 (10.2e14.8)
60e69 9.6 (7.0e12.2) 15.3 (12.2e18.4)
70e79 10.3 (7.1e13.6) 14.8 (11.5e18.2)
80þ 10.6 (5.3e15.8) 12.7 (8.6e16.7)
Center
St. John’s, Newfoundland 2.2 (0.0e5.2) 2.7 (0.0e5.9)
Halifax, Nova Scotia 4.1 (1.5e6.7) 5.8 (2.8e8.7)
Quebec City, Quebec 3.3 (2.1e4.4) 8.0 (6.3e9.7)
Kingston, Ontario 2.8 (0.0e7.2) 5.9 (0.0e11.8)
Toronto, Ontario 4.4 (3.2e5.5) 6.9 (5.5e8.3)
Hamilton, Ontario 3.1 (0.5e5.7) 7.5 (3.7e11.3)
Saskatoon, Saskatchewan 6.0 (3.0e9.0) 8.2 (4.9e11.5)
Calgary, Alberta 5.5 (3.1e7.8) 10.2 (7.1e13.3)
Vancouver, British Columbia 8.6 (6.1e11.1) 13.0 (10.1e15.8)
Education*
<Grade 9 2.6 (0.3e4.8) 11.1 (7.3e14.8)
Grade 9e13, No Diploma 4.4 (2.7e6.2) 11.6 (9.1e14.2)
High School Diploma 3.5 (1.9e5.0) 7.8 (5.8e9.8)
Trade/Professional Diploma 4.0 (2.6e5.3) 10.0 (7.9e12.0)
University without Diploma 3.3 (1.3e5.4) 5.7 (3.4e8.0)
University with Diploma 7.6 (3.8e11.5) 4.6 (2.1e7.0)
University Degree(s) 6.3 (4.9e7.6) 6.2 (4.7e7.8)
*For Education, all references to a diploma were collected as
‘‘Certiﬁcate or Diploma’’.
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Glucosamine use and bone or joint disease, using values standardized to the Canadian population. Percentages in the Status columns are
based on the total sample. Percentages in the glucosamine use column are based on status of condition (row)
Comorbidity Men Women
N¼ 3667 N¼ 174 N¼ 3985 N¼ 329
Status of condition Glucosamine use Status of condition Glucosamine use
Percent and 95% CI*
Rheumatoid arthritis or osteoarthritis
Do not know 0.0 (0.0e0.1) e 0.1 (0.0e0.3) e
No 81.6 (80.3e82.8) 3.1 (2.5e3.8) 72.4 (71.0e73.7) 5.2 (4.4e6.1)
Yes, at baseline already 13.1 (12.0e14.2) 13.4 (10.3e16.4) 19.8 (18.6e21.1) 16.6 (14.0e19.2)
Yes, developed since then 5.3 (4.5e6.0) 8.2 (4.4e12.1) 7.7 (6.8e8.5) 15.2 (11.2e19.2)
Osteoporosis
Do not know e e 0.0 (0.0e0.1) e
No 94.3 (93.6e95.1) 4.6 (3.9e5.3) 85.5 (84.4e86.6) 7.4 (6.6e8.3)
Yes, at baseline already 0.8 (0.5e1.1) e 4.6 (3.9e5.2) 14.7 (9.5e19.8)
Yes, developed since then 4.9 (4.2e5.6) 9.1 (4.9e13.3) 9.9 (8.9e10.8) 12.2 (9.0e15.5)
Family history of osteoarthritis
Do not know 6.7 (5.8e7.5) 1.9 (0.2e3.6) 5.0 (4.3e5.7) 8.5 (4.6e12.4)
No 68.5 (67.0e70.0) 4.6 (3.7e5.4) 68.0 (66.6e69.5) 8.0 (7.0e9.1)
Yes 24.9 (23.5e26.3) 6.0 (4.5e7.5) 27.0 (25.6e28.3) 8.7 (7.0e10.4)
Any history of fracture
Do not know 2.0 (1.5e2.4) 0.2 (0.0e1.3) 1.7 (1.3e2.1) 6.7 (0.7e12.8)
No 75.2 (73.8e76.6) 5.4 (4.6e6.2) 75.0 (73.6e76.3) 8.0 (7.0e8.9)
Yes, at baseline already 21.1 (19.7e22.4) 2.5 (1.4e3.6) 19.1 (17.9e20.4) 8.2 (6.3e10.2)
Yes, fractured since then 1.8 (1.4e2.2) 8.4 (1.7e15.1) 4.2 (3.6e4.9) 13.8 (8.6e19.0)
Ever had back pain
No 37.9 (36.3e39.4) 4.1 (3.1e5.2) 39.5 (38.0e41.0) 6.3 (5.1e7.5)
Yes 62.1 (60.6e63.7) 5.1 (4.2e6.0) 60.5 (59.0e62.2) 9.5 (8.4e10.7)
Note: Numbers do not always add to totals due to rounding. For women, 0.02% had missing data or refused to respond to the family history
question.
*CI¼Conﬁdence Interval.use was much higher in those with than in those without
arthritis.
Table IV reports on a multivariable logistic regression
model examining factors associated with glucosamine
use. The age group of 30e39 years had an insufﬁcient
number of glucosamine users to act as a reference group;
therefore the age group of 40e49 years was used as the
reference category. All age groups had a higher odds ratio
(OR) for taking glucosamine as compared to the reference
category. All centers had a higher OR for glucosamine
use as compared to St. John’s, the reference center,
although the difference between Kingston and St. John’s
appears to be small. Participants were also more likely to
use glucosamine if they reported a diagnosis of arthritis ei-
ther at baseline or in the following 5 years, with a somewhat
higher likelihood associated with a more recent diagnosis.
Those who had experienced back pain at some point, had
a higher calcium intake and who engaged in regular physi-
cal activity were also more likely to take glucosamine. The
strongest determinant of glucosamine use at the 5-year
follow-up was glucosamine use at baseline [OR¼ 4.4;
95% conﬁdence interval (CI)¼ 3.0e6.5].
Discussion
AGE AND GENDER
Glucosamine use increased substantially over 5 years,
particularly among women and with increasing age. Age
was included in the ﬁnal regression model, but gender wasnot among the best combination of factors associated with
glucosamine use, despite the fact that the univariate analysis
suggested that women were 1.5 times more likely to take
glucosamine as compared to men (95% CI 1.3e1.8). These
ﬁndings provide some support for previous ﬁnding regarding
the association between age, gender and CAM use,
although the other data are not speciﬁc to glucosamine1,2.
ARTHRITIS AND BACK PAIN
Six hundred and seventy-ﬁve men and 1096 women had
been told that they had arthritis, either at baseline or in the 5
years since then. From Table III, it is clear that glucosamine
use was much higher in these participants than in those
who did not have arthritis. These higher rates have been
noted in other research1,6, and would be expected, as glu-
cosamine is primarily marketed for the relief of arthritis
symptoms5e7. In fact, one of these studies, conducted
among patients with osteoarthritis and rheumatoid arthritis,
found an even stronger association between arthritis and
glucosamine use than our study6. However, that study
was conducted in a clinic-based population, and thus may
have included participants with more severe disease and
subsequent higher rates of use. The association between
glucosamine use and back pain is consistent with other
ﬁndings that suggest that CAM and/or glucosamine are
commonly used to treat arthritic pain, as well as back
pain, back problems, neck pain and joint stiffness, which
may be manifestations of arthritic pain1,5,6,17.
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For women, glucosamine use decreased as education
increased, while for men, there was a small increase with
higher levels of education. Published data show mixed
results, with some reports reﬂecting an association between
CAM and higher education1,6, no association with educa-
tion5, and an inverse association2. Education was not
included in the ﬁnal model, but the univariate results are
inconclusive, as the CIs for education were quite wide,
with univariate ORs ranging from a low of 1.1 (95% CI
0.8e1.5) for those with a high school diploma, to a high of
1.4 (95% CI 1.1e1.8) for those with a university degree(s).
REGION
Our data also suggest a trend of increased glucosamine
use as one moves westward within Canada. Compared to
the eastern centers in Newfoundland, Nova Scotia, Quebec
and the three Ontario centers, use of glucosamine was
higher in the centers located in the Prairie Provinces (Sas-
katoon and Calgary), with highest usage being reported in
the most western center (Vancouver) (Table IV). A similar
pattern is seen in the US, where states classiﬁed as
‘‘West’’ and ‘‘Paciﬁc’’ had higher rates of CAM use and in
particular, BBT use, as compared to the states listed as
‘‘Northeast’’, ‘‘Midwest’’ and ‘‘South’’1.
PERSONAL HEALTH MANAGEMENT AND ACTIVITY
Another commonly cited reason for CAM use is that of
personal health management, as part of preventive health
care rather than as a treatment for illness4. In fact, large
Table IV
Multivariable logistic regression model for glucosamine use
Variable ORs and 95% CIs
Age group (reference group¼ 40e49 years)*
50e59 2.52 (1.43, 4.44)
60e69 3.18 (1.82, 5.55)
70e79 3.21 (1.84, 5.58)
80þ 2.50 (1.40, 4.47)
Center (reference group¼St. John’s, Newfoundland)
Halifax, Nova Scotia 1.43 (0.96, 2.13)
Quebec City, Quebec 1.86 (1.26, 2.74)
Kingston, Ontario 1.20 (0.80, 1.80)
Hamilton, Ontario 1.60 (1.09, 2.35)
Toronto, Ontario 1.83 (1.22, 2.73)
Saskatoon, Saskatchewan 2.20 (1.51, 3.19)
Calgary, Alberta 2.73 (1.89, 3.94)
Vancouver, British Columbia 3.08 (2.13, 4.44)
Arthritis (reference group¼No)
Yes, at baseline 2.29 (1.94, 2.71)
Yes, developed since baseline 2.90 (2.28, 3.67)
Ever had back pain (reference group¼No)
Yes 1.38 (1.17, 1.64)
Daily calcium intake from supplements, year 5
For every 300 mg consumed 1.18 (1.13, 1.23)
Regular physical activity (reference group¼No)
Yes 1.26 (1.09, 1.47)
Glucosamine use at baseline (reference group¼No)
Yes 4.42 (3.01, 6.51)
*There were insufﬁcient numbers of glucosamine users in the
30e39 year age group to serve as a reference population.numbers of Canadians indicated that CAM was useful for
maintaining or promoting health (77%), or for treating illness
(68%)4. There is also evidence to suggest that athletes use
products such as glucosamine as preventive management
in addition to its use for pain, swelling and arthritis10. This
may explain the association between participation in regular
physical activity and glucosamine use. Those who are
physically active may take glucosamine because the activ-
ity aggravates conditions such as arthritis, or they may use
it prophylactically, to protect against the degenerative
changes associated with arthritis.
The concept of using glucosamine prophylactically has
received some support from a systematic review that sug-
gests that glucosamine was more effective than placebo
in delaying structural progression of knee osteoarthritis12.
An overview of the treatment strategies for OA also identi-
ﬁed several studies that found a beneﬁcial structural effect
of glucosamine sulfate19. Further information about the abil-
ity of glucosamine to delay structural damage of knee OA
will be available when the GAIT study releases additional
ﬁndings later this year15.
CALCIUM INTAKE FROM SUPPLEMENTS
The association between higher calcium intake from
supplements and the use of glucosamine has not been
demonstrated in previous research, possibly because
much of the previous research was based on survey data
where speciﬁc details regarding use of other supplements
may not have been collected. One possible explanation
may be the relatively high use among the participants with
osteoporosis in the CaMos sample. While a diagnosis of
osteoporosis was not strongly associated with glucosamine
use, the univariate analysis presented in Table III does
suggest a higher use of glucosamine in those with osteopo-
rosis, particularly among women. These participants are
also likely to be taking calcium supplementation, which
may have led to the higher calcium intake in glucosamine
users. The participants were aware of being in an osteopo-
rosis study, and might therefore be expected to be more
aware of calcium and its link to osteoporosis.
A second explanation may involve health promotion, in
that those who are taking glucosamine for personal health
management may also be eating healthier diets. In fact,
there may be two groups of participants who use glucos-
amine, one that is using it to manage pain and symptoms
of arthritis and back pain, and a second that has a healthy
lifestyle and takes glucosamine as a preventive measure.
This is supported by recent research, which noted that
BBT (including glucosamine) were used almost equally for
treatment and for prevention20.
LIMITATIONS
Limitations of the research must be acknowledged.
Although the CaMos participants were randomly selected,
not all who were invited to participate did so, and those
who did not may have differed in some way from those
who did agree to participate. Moreover, our data do not
allow us to fully explore rural regions. Although the 50-km
radius around each urban center included rural areas, the
sample did include a much higher proportion of urban com-
pared to rural residents. Close to 20% of the original sample
did not provide data at 5 years for a variety of reasons, and
those who were still alive but chose not to participate may
have differed in important ways, such as illness, from those
1293Osteoarthritis and Cartilage Vol. 14, No. 12who did participate at 5 years. Finally, after 5 years of par-
ticipating in a study focusing on lifestyle and risk factors for
osteoporosis, there may be a study effect in that this cohort
may be more aware of their health and take steps to
preserve it, as compared to those not in the study. Never-
theless, these data do provide insight into the prevalence
of and factors associated with glucosamine use in a popula-
tion-based sample.
Conclusions
The existing literature suggests that the use of CAM and
glucosamine in particular is at an all-time high, and that this
trend is likely to continue1,2,4. Our data suggest that the use
of glucosamine has increased over a 5-year period in a ran-
dom sample of Canadians, and that this is associated with
age, region of Canada, arthritis, back pain, calcium intake,
regular physical activity and glucosamine use 5 years
earlier. Some may use glucosamine to manage pain and
symptoms of arthritis and back pain, while others may use
it as a preventive measure to maintain health.
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